Zikai He1, Hana Morrissey2, Patrick Ball2. 1. Charles Darwin University, Australia. Electronic address: zikaihe@hotmail.com. 2. Charles Darwin University, Australia.
Abstract
BACKGROUND: The current debate over the optimal Enoxaparin prophylactic dosing strategies in obese patients centre around whether it should be based on the actual weight of the patient (i.e. weight-based), or at an artificially fixed amount, as it is the case in Australia (40mg daily). The vast majority of the evidence available today is laboratory-based, measuring serum Antifactor-Xa activities as a marker for physiological response. AIM: The aim of the parent study is to compare the clinical outcomes for obese patients who received fixed doses of enoxaparin compared to those who received weight-based doses within the licensed dosage recommendations. This review was conducted to examine whether a gap in knowledge exists in relation to dosing obese patients with enoxaparin as VTE prophylaxis after hospital admission to aid in development of the parent study concept. METHOD: Databases such as Medline, EBSCOhost, ProQuest were interrogated using combinations of words such as "enoxaparin", AND "dosing strategy", AND "obese/obesity" AND "prophylaxis". Only eleven out of 14 primary studies which were considered to be sufficiently similar in methodology and anticipated outcomes were reviewed and analysed. RESULTS: Pooled data from the eleven studies suggested that weight-based or higher-than-fixed dosing had a 36.2% higher success rate than fixed dosing, and was more likely to achieve the desired serum Anti-Xa activity levels (52.2% and 16% respectively). The rate of failure to achieve this is significantly lower in the weight-based groups (13.3%) than in fixed-dose groups (18.5%). These eleven studies reviewed included 601 patients in total. CONCLUSION: There is insufficient evidence to support or negate the current enoxaparin health outcomes in obese and very obese patients due to the lack of post-discharge follow-up from hospitals. Further research is required to compare long-term outcomes after fixed and weight-based dosing of enoxaparin. The optimal dose of enoxaparin per kilogram of body weight for prophylaxis remains to be determined.
BACKGROUND: The current debate over the optimal Enoxaparin prophylactic dosing strategies in obesepatients centre around whether it should be based on the actual weight of the patient (i.e. weight-based), or at an artificially fixed amount, as it is the case in Australia (40mg daily). The vast majority of the evidence available today is laboratory-based, measuring serum Antifactor-Xa activities as a marker for physiological response. AIM: The aim of the parent study is to compare the clinical outcomes for obesepatients who received fixed doses of enoxaparin compared to those who received weight-based doses within the licensed dosage recommendations. This review was conducted to examine whether a gap in knowledge exists in relation to dosing obesepatients with enoxaparin as VTE prophylaxis after hospital admission to aid in development of the parent study concept. METHOD: Databases such as Medline, EBSCOhost, ProQuest were interrogated using combinations of words such as "enoxaparin", AND "dosing strategy", AND "obese/obesity" AND "prophylaxis". Only eleven out of 14 primary studies which were considered to be sufficiently similar in methodology and anticipated outcomes were reviewed and analysed. RESULTS: Pooled data from the eleven studies suggested that weight-based or higher-than-fixed dosing had a 36.2% higher success rate than fixed dosing, and was more likely to achieve the desired serum Anti-Xa activity levels (52.2% and 16% respectively). The rate of failure to achieve this is significantly lower in the weight-based groups (13.3%) than in fixed-dose groups (18.5%). These eleven studies reviewed included 601 patients in total. CONCLUSION: There is insufficient evidence to support or negate the current enoxaparin health outcomes in obese and very obesepatients due to the lack of post-discharge follow-up from hospitals. Further research is required to compare long-term outcomes after fixed and weight-based dosing of enoxaparin. The optimal dose of enoxaparin per kilogram of body weight for prophylaxis remains to be determined.
Authors: Alexandria J Robbins; Mariya E Skube; Melena D Bellin; Ty B Dunn; Scott A Chapman; K Louise Berry; Elizabeth Lusczek; Gregory J Beilman Journal: Pancreas Date: 2019 Nov/Dec Impact factor: 3.327
Authors: Connor M Bunch; Ernest E Moore; Hunter B Moore; Matthew D Neal; Anthony V Thomas; Nuha Zackariya; Jonathan Zhao; Sufyan Zackariya; Toby J Brenner; Margaret Berquist; Hallie Buckner; Grant Wiarda; Daniel Fulkerson; Wei Huff; Hau C Kwaan; Genevieve Lankowicz; Gert J Laubscher; Petrus J Lourens; Etheresia Pretorius; Maritha J Kotze; Muhammad S Moolla; Sithembiso Sithole; Tongai G Maponga; Douglas B Kell; Mark D Fox; Laura Gillespie; Rashid Z Khan; Christiaan N Mamczak; Robert March; Rachel Macias; Brian S Bull; Mark M Walsh Journal: Front Surg Date: 2022-05-04
Authors: Alex C Spyropoulos; Jean M Connors; James D Douketis; Mark Goldin; Beverley J Hunt; Taiwo R Kotila; Renato D Lopes; Sam Schulman Journal: J Thromb Haemost Date: 2022-07-29 Impact factor: 16.036
Authors: Jacqueline G Gerhart; Fernando O Carreño; Matthew Shane Loop; Craig R Lee; Andrea N Edginton; Jaydeep Sinha; Karan R Kumar; Carl M Kirkpatrick; Christoph P Hornik; Daniel Gonzalez Journal: Clin Pharmacol Ther Date: 2022-05-18 Impact factor: 6.903